Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 12, 2007 Jeremy MacNealy	Fool on Call: Chattem Looks Toward a Record '08 Timely acquisitions and cost savings add up to a big year for this consumer-goods producer. Prospective investors should at least take a closer look.
The Motley Fool October 11, 2006 Brian Lawler	Monopoly Woes Help Chattem Grow Acquisitions boost the health-care brand owner's shares to new highs.
The Motley Fool February 13, 2007 Rich Duprey	Chattem Has Relief on the Way The consumer products company has a portfolio of new products to drive revenues and profits. Investors, take note.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Chattem Chugs Along Shares of Chattem hit a new high today on solid results, and management ups its guidance, but what does that mean going forward? Investors should take note.
The Motley Fool March 19, 2007 Rich Duprey	Foolish Forecast: Chatting Up Chattem The consumer products company will report first-quarter 2007 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool July 10, 2006 Stephen D. Simpson	Chattem Holds Its Ground Management seems to have more faith in this consumer-goods company's business than Wall Street does. It is likely not a stock for the faint of heart.
The Motley Fool July 11, 2007 Brian Orelli	Icy Hot Results From Chattem The manufacturer of over-the-counter health-care products sees a huge increase in sales, but can it last? Investors, take note.
The Motley Fool April 17, 2006 Stephen D. Simpson	Chattin' Up Chattem Great brands owned by a boring and unknown company. Might there be value afoot for investors?
The Motley Fool September 20, 2005 Jeremy MacNealy	Chattem's Icy Hot Stock The stock of this manufacturer of over-the-counter health-care products is on an exceptional run. Shareholders may be wondering whether this is a good time to take some money off the table.
The Motley Fool June 20, 2005 Matt Thurmond	Chattem's High-Dollar Brands Health-care product maker generates big bucks from the body's annoying little problems.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool September 26, 2007 Ryan Fuhrmann	Foolish Forecast: Will Chattem's Recent Results Prove Soothing? In advance of earnings reports at the health-care and consumer-products firm, analysts are projecting 47% year-over-year growth due to recently acquired brands.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years.
The Motley Fool December 22, 2009 Brian Orelli	This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool January 12, 2006 Stephen D. Simpson	The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
BusinessWeek December 20, 2004 Amy Barrett	J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.
The Motley Fool September 28, 2009 Brian Orelli	The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool July 26, 2005 Rich Smith	J&J: One Pricey Stock This giant of the health-care world reported its second quarter 2005 earnings last week but, by all appearances, failed to impress Wall Street. Johnson & Johnson's become very big, very pricey.
The Motley Fool April 16, 2008 Brian Orelli	Johnson & Johnson Chugs Along Strong growth, mostly from the weak dollar, fails to excite Johnson & Johnson's investors.
The Motley Fool May 2, 2011 Anupama Pattanaik	J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion.
The Motley Fool November 3, 2005 Stephen D. Simpson	The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific.
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk.
The Motley Fool August 24, 2010 Matt Koppenheffer	How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?
The Motley Fool May 12, 2010 Nick Kapur	J&J: A Winner on Both Sides of the Ball (Fool TV) If you're looking to build a dynasty in your portfolio, you'd be hard-pressed to find a better-balanced outfit than veteran Johnson & Johnson. The consumer products giant is discussed in this video.
The Motley Fool April 13, 2006 Doug Short	A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock.
BusinessWeek April 17, 2006 Amy Barrett	J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
BusinessWeek June 18, 2007 Arlene Weintraub	J&J's New Baby As other divisions stumble, Johnson & Johnson's consumer products - bolstered by a $16.6 billion addition - provide a security blanket.
The Motley Fool October 12, 2007 Ryan Fuhrmann	Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors.
The Motley Fool November 7, 2005 Stephen D. Simpson	All's Not Lost at Guidant Eroding sales, a partner with cold feet, and all sorts of litigation and investigation cloud Guidant's skies. Investors, take note.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool January 24, 2005 Dave Marino-Nachison	J&J Snack Foods Won't Spoil Dinner The SuperPretzel and ICEE company looks like a solid performer that can grow. The stock seems fully valued at current prices and given the market's earnings estimates.
The Motley Fool November 29, 2007 Anders Bylund	Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson.